IMPEDIMED LIMITED — Capital/Financing Update 2010

May 11, 2010

==> picture [81 x 92] intentionally omitted <==

12 May 2010

Australian Securities Exchange Announcement

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES OR TO US PERSONS

ImpediMed Limited Announces Successful Completion of Entitlement Offer

ImpediMed Limited (“ ImpediMed ” or the “ Company ”) is pleased to announce the results of the 1 for 8 non-renounceable entitlement offer announced on 1 April 2010 (“ Entitlement Offer ”).

ImpediMed received applications under the Entitlement Offer totaling approximately A$7.5 million which comprises approximately A$4.3 million in entitlement acceptances and approximately A$3.2 million in applications for additional shares.

All shareholders who submitted valid applications for their entitlements and for additional shares will receive 100% of their applications.

As a result of the Entitlement Offer, a total of 11,567,763 new shares will be issued by ImpediMed increasing the total number of fully paid ordinary shares on issue to 135,718,793.

As previously announced, the Directors reserve the right to place the shortfall of 3,951,116 ordinary shares under the Entitlement Offer within 3 months of the closing date of the Entitlement Offer.

In accordance with the timetable for the Entitlement Offer, it is currently anticipated that:

• allotment and issue of all shares under the Entitlement Offer will occur on 17 May 2010;

• normal trading of the new shares will commence on 18 May 2010; and

• holding statements for new shares will be dispatched by 19 May 2010.

Shareholders who applied for shares under the Entitlement Offer and want to trade these shares before receiving their holding statements should confirm their allocation before doing so.

CEO of ImpediMed Greg Brown said: “We are pleased with the result of the Entitlement Offer, particularly considering the difficult market conditions of last week. The proceeds from the Entitlement Offer, together with the proceeds received by the Company from it’s

In Australia: ImpediMed Limited Unit 1 50 Parker Court Pinkenba, QLD 4008 Phone : +61-7-3860-3700

ASX CODE: IPD

ImpediMed Limited ABN 47 106 092 577 Website: www.impedimed.com

A$10 million institutional placement (announced to the market on 9 April 2010), will allow the Company to further facilitate adoption of L-Dex technology by surgeons and oncologists, primarily in the US.”

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

This announcement has been prepared for publication in Australia and may not be distributed or released in the United States. This announcement does not constitute an offer of shares for sale in the United States or in any other jurisdiction in which such an offer would be illegal. The new shares the subject of this capital raising have not been, and will not be, registered under the US Securities Act of 1933 and, accordingly, may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of such Act and applicable US state securities laws.

ASX CODE: IPD

In Australia: ImpediMed Limited Unit 1 50 Parker Court Pinkenba, QLD 4008 Phone : +61-7-3860-3700

Website: www.impedimed.com